Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Cervical Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 77 articles: HTML format

Single Articles

November 2025
1. ORTEGA LLOBET M, Gray P, Baussano I, Elfstrom KM, et al
   Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women.
   Int J Cancer. 2025 Nov 7. doi: 10.1002/ijc.70229.
   PubMed     Abstract available
   
   
   
2. SA P, Monteiro P, Henrique R, Lunet N, et al
   The cervical cancer screening program in the North of Portugal: Outcomes after nearly two decades of coexistence with the human papillomavirus vaccine.
   Int J Cancer. 2025 Nov 3. doi: 10.1002/ijc.70196.
   PubMed     Abstract available
   
   
   October 2025
3. CHINULA L, Chagomerana MB, Mkochi T, Msowoya L, et al
   Single visit screen-triage-treat strategy using GeneXpert-based HPV testing of self-collected cervicovaginal samples and thermal ablation treatment for cervical cancer prevention among women in Lilongwe, Malawi.
   Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70177.
   PubMed     Abstract available
   
   
   
4. YU X, Nzoutchoum OL, Gao D, Hsu CD, et al
   Cervical cancer screening and prevalence among older US Medicare beneficiaries with and without HIV.
   Int J Cancer. 2025 Oct 13. doi: 10.1002/ijc.70193.
   PubMed     Abstract available
   
   
   September 2025
5. KOESTLER AJ, Nelson CW, Yeager M, Chen Z, et al
   Whole-genome sequencing of 1,083 HPV45 cases and controls identifies genetic variants associated with glandular cervical lesions.
   Int J Cancer. 2025;157:1130-1141.
   PubMed     Abstract available
   
   
   
6. ANDERSEN K, Bonde J, Waldstrom M, Jakobsen MV, et al
   Evaluation of targeted next-generation sequencing for detection of HPV genotypes and sublineages in cervical liquid-based cytology SurePath samples from the Danish screening program.
   Int J Cancer. 2025 Sep 11. doi: 10.1002/ijc.70148.
   PubMed     Abstract available
   
   
   
7. LIU H, Zou Z, Zhang L
   Reply to 'Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis"'.
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70129.
   PubMed    
   
   
   
8. LIU Z, Tong X
   Comments on "HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis".
   Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70130.
   PubMed    
   
   
   
9. CASTANEDA KM, Vermeulen KM, van der Aa M, Schuuring E, et al
   Trends in cervical cancer incidence in the Netherlands: A join-point and age-period-cohort analysis (1989-2023).
   Int J Cancer. 2025 Sep 8. doi: 10.1002/ijc.70134.
   PubMed     Abstract available
   
   
   July 2025
10. BOWDEN SJ, Bodinier B, Paraskevaidi M, Kalliala I, et al
    DNA methylation signatures of cervical pre-invasive and invasive disease: An epigenome-wide association study.
    Int J Cancer. 2025;157:305-316.
    PubMed     Abstract available
    
    
    
11. BJORGE T, Stoer NC, Hverven SK, Nygard M, et al
    Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.
    Int J Cancer. 2025;157:251-259.
    PubMed     Abstract available
    
    
    
12. CHANDRAN A, Mackie A, Sasieni P, Arbyn M, et al
    Technical, legal and ethical framework of cancer audit in cervical screening - Summary of best practices for organised programmes delineated through an expert group consultation.
    Int J Cancer. 2025;157:32-40.
    PubMed     Abstract available
    
    
    June 2025
13. ZHENG Y, Han J, Qu Y, Wang J, et al
    DNA methylation biomarkers for cervical cancer risk prediction in HIV-positive Nigerian women.
    Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35502.
    PubMed     Abstract available
    
    
    
14. JENKINS M, Saidu R, Boa R, Mbatani N, et al
    Performance of thermoablation among women treated for high-risk human papillomavirus in a screen-and-treat program in South Africa.
    Int J Cancer. 2025 Jun 6. doi: 10.1002/ijc.35519.
    PubMed     Abstract available
    
    
    May 2025
15. DAMGAARD R, Jenkins D, Stoler MH, van de Sandt M, et al
    p16(INK4a) and HPV E4 immunohistochemistry for the prediction of regression of cervical intraepithelial neoplasia grade 2-A historical cohort study.
    Int J Cancer. 2025 May 5. doi: 10.1002/ijc.35469.
    PubMed     Abstract available
    
    
    April 2025
16. KALJOUW S, Jansen EEL, Schevenhoven VJC, de Kok IMCM, et al
    Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? A modelling study using cohort effects.
    Int J Cancer. 2025 Apr 28. doi: 10.1002/ijc.35435.
    PubMed     Abstract available
    
    
    
17. WEI Y, Gu L, Zhang Y, Yang Q, et al
    Efficacy of ALA-PDT in treating cervical low-grade squamous intraepithelial lesions with high-risk HPV patients: A multicentre randomized controlled trial.
    Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35450.
    PubMed     Abstract available
    
    
    March 2025
18. ESLAHI M, Pizzato M, Heikkinen S, Martinsen JI, et al
    Socioeconomic position and risk of cervical cancer in the Nordic countries: Results from the Nordic Occupational Cancer Study.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35349.
    PubMed     Abstract available
    
    
    
19. LI Z, Liu P, Yin A, Zhang B, et al
    Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer.
    Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35369.
    PubMed     Abstract available
    
    
    
20. CHEN Q, Yao X, Quan J, Jia X, et al
    The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort study.
    Int J Cancer. 2025;156:1043-1054.
    PubMed     Abstract available
    
    
    February 2025
21. KEBEDE HB, Mekuria S, Asegid N, Forslund O, et al
    High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia: A community-based cohort study.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35335.
    PubMed     Abstract available
    
    
    
22. HARPER DM, Paczos T, Ridder R, Huh WK, et al
    p16/ki-67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions.
    Int J Cancer. 2025 Feb 4. doi: 10.1002/ijc.35353.
    PubMed     Abstract available
    
    
    January 2025
23. DU L, Sun H, Tang L, Hao S, et al
    Cervical cancer incidence rates considering migration status in mainland China using Bayesian model-Estimation based on 2016 cancer registry data.
    Int J Cancer. 2025 Jan 23. doi: 10.1002/ijc.35346.
    PubMed     Abstract available
    
    
    
24. ARROYO MUHR LS, Wang J, Hassan SS, Yilmaz E, et al
    Nationwide registry-based trial of risk-stratified cervical screening.
    Int J Cancer. 2025;156:379-388.
    PubMed     Abstract available
    
    
    December 2024
25. VERHOEF L, Bleeker MCG, Polman N, Kroon KR, et al
    Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35289.
    PubMed     Abstract available
    
    
    
26. KEN-AMOAH S, Redl E, Domson BKS, Barrett JE, et al
    Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana.
    Int J Cancer. 2024 Dec 10. doi: 10.1002/ijc.35260.
    PubMed     Abstract available
    
    
    November 2024
27. PEDERSEN BT, Sonne SB, Pedersen H, Andreasen EK, et al
    Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.
    Int J Cancer. 2024 Nov 23. doi: 10.1002/ijc.35263.
    PubMed     Abstract available
    
    
    
28. LIU H, Zou M, Shen M, Kamarulzaman A, et al
    HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
    Int J Cancer. 2024 Nov 17. doi: 10.1002/ijc.35242.
    PubMed     Abstract available
    
    
    
29. SCHAAFSMA M, Schuurman TN, Kootstra P, Issa D, et al
    Nationwide cohort study on the risk of high-grade cervical dysplasia and carcinoma after conservative treatment or hysterectomy for adenocarcinoma in situ.
    Int J Cancer. 2024 Nov 4. doi: 10.1002/ijc.35237.
    PubMed     Abstract available
    
    
    
30. LOUVANTO K, Verhoef L, Pimenoff V, Eriksson T, et al
    Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions.
    Int J Cancer. 2024;155:1549-1557.
    PubMed     Abstract available
    
    
    October 2024
31. DESCAMPS P, Bosch Jose FX, Monsonego J, Neisingh O, et al
    Cervical cancer screening: Sharing best practices and addressing common challenges in cervical cancer screening programs.
    Int J Cancer. 2024 Oct 26. doi: 10.1002/ijc.35220.
    PubMed    
    
    
    
32. LEHTINEN M, Elfstrom M, Vanska S, Dillner J, et al
    Elimination of cervical cancer by refined vaccination and screening.
    Int J Cancer. 2024 Oct 25. doi: 10.1002/ijc.35228.
    PubMed    
    
    
    
33. KOKEMULLER L, Ramachandran D, Schurmann P, Geffers R, et al
    Germline variants of homology-directed repair or mismatch repair genes in cervical cancer.
    Int J Cancer. 2024 Oct 23. doi: 10.1002/ijc.35221.
    PubMed     Abstract available
    
    
    
34. MISHRA GA, Pimple SA, Anand KV, Kulkarni VY, et al
    Acceptability and validity of HPV self-sampling for cervical cancer screening among women living in different ecological settings in India.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35222.
    PubMed     Abstract available
    
    
    
35. CUI M, Song L, Mao R, Lyu Y, et al
    Exposure to polycyclic aromatic hydrocarbons promotes the progression of low-grade cervical intraepithelial neoplasia: A population-based cohort study in China.
    Int J Cancer. 2024;155:1162-1171.
    PubMed     Abstract available
    
    
    September 2024
36. CHEN J, Shi J, Cao Y, Li C, et al
    A new treatment approach of toripalimab in combination with concurrent platinum-based chemoradiotherapy for locally advanced cervical cancer: A phase II clinical trial.
    Int J Cancer. 2024 Sep 28. doi: 10.1002/ijc.35206.
    PubMed     Abstract available
    
    
    
37. DEBEAUDRAP P, Kabore FN, Setha L, Tegbe J, et al
    Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35190.
    PubMed     Abstract available
    
    
    
38. OSTRBENK VALENCAK A, Kroon KR, Fabjan D, Mlakar J, et al
    Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.
    Int J Cancer. 2024 Sep 24. doi: 10.1002/ijc.35200.
    PubMed     Abstract available
    
    
    
39. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
    Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Int J Cancer. 2024;155:905-915.
    PubMed     Abstract available
    
    
    August 2024
40. SCHAAFSMA M, van den Helder R, Mom CH, Steenbergen RDM, et al
    Recurrent cervical cancer detection using DNA methylation markers in self-collected samples from home.
    Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35143.
    PubMed     Abstract available
    
    
    July 2024
41. LYNGE E, Bennekou Schroll J, Andersen B, Balasubramaniam K, et al
    Cervical cancer incidence in Denmark: Disentangling determinants of time trend.
    Int J Cancer. 2024 Jul 14. doi: 10.1002/ijc.35081.
    PubMed     Abstract available
    
    
    
42. MORO F, Ciancia M, Zace D, Vagni M, et al
    Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review.
    Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35092.
    PubMed     Abstract available
    
    
    
43. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
    Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
    Int J Cancer. 2024;155:81-92.
    PubMed     Abstract available
    
    
    May 2024
44. LOBIN C, Orang'o EO, Were E, Muthoka K, et al
    Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya.
    Int J Cancer. 2024 May 27. doi: 10.1002/ijc.35036.
    PubMed     Abstract available
    
    
    
45. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
    Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
    Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
    PubMed     Abstract available
    
    
    April 2024
46. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    PubMed     Abstract available
    
    
    
47. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
    Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
    PubMed     Abstract available
    
    
    March 2024
48. PORTNOY A, Pedersen K, Sy S, Trope A, et al
    Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Int J Cancer. 2024;154:1073-1081.
    PubMed     Abstract available
    
    
    
49. LI N, Yi H, Sun W, Sundquist J, et al
    Revealing genes associated with cervical cancer in distinct immune cells: A comprehensive Mendelian randomization analysis.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34911.
    PubMed     Abstract available
    
    
    
50. STERPETTI AV, Gabriele R, Iannone I, Sapienza P, et al
    Reduced adherence to cervical cancer screening. The importance of information and education for women with low education and low-income.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34907.
    PubMed    
    
    
    
51. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
    The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
    PubMed     Abstract available
    
    
    February 2024
52. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    PubMed     Abstract available
    
    
    
53. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
    Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
    Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
    PubMed     Abstract available
    
    
    January 2024
54. AMBOREE TL, Damgacioglu H, Sonawane K, Adsul P, et al
    Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000-2019.
    Int J Cancer. 2024 Jan 25. doi: 10.1002/ijc.34860.
    PubMed     Abstract available
    
    
    
55. LEHTINEN M, Bruni L, Elfstrom M, Gray P, et al
    Scientific approaches toward improving cervical cancer elimination strategies.
    Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34839.
    PubMed     Abstract available
    
    
    
56. EL-ZEIN M, Cheishvili D, Szyf M, Franco EL, et al
    Validation of novel DNA methylation markers in cervical precancer and cancer.
    Int J Cancer. 2024;154:104-113.
    PubMed     Abstract available
    
    
    December 2023
57. 
    Harald zur Hausen 1936-2023.
    Int J Cancer. 2023;153:1937-1939.
    PubMed    
    
    
    
58. DICK S, Heideman DAM, Mom CH, Meijer CJLM, et al
    Methylation testing for the detection of recurrent cervical intraepithelial neoplasia.
    Int J Cancer. 2023;153:2011-2018.
    PubMed     Abstract available
    
    
    November 2023
59. TULSIDAS S, Fontes F, Monteiro K, Mussa M, et al
    Cervical cancer in Mozambique: Clinical characteristics, treatment and survival of incident cases admitted to the Oncology Service of Maputo Central Hospital in 2016-2018.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34779.
    PubMed     Abstract available
    
    
    
60. BONI SP, Tenet V, Horo A, Heideman DAM, et al
    High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020.
    Int J Cancer. 2023 Nov 9. doi: 10.1002/ijc.34774.
    PubMed     Abstract available
    
    
    October 2023
61. 
    Correction to "Randomized multicenter phase II trial of prophylactic irradiation of para-aortic lymph nodes in advanced cervical cancer according to tumor hypoxia: Korean Radiation Oncology Group (KROG 07-01) study".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34775.
    PubMed    
    
    
    
62. COCUZZA CE, Dhillon SK, Martinelli M, Giubbi C, et al
    Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34754.
    PubMed     Abstract available
    
    
    September 2023
63. INTURRISI F, de Sanjose S, Desai KT, Dagnall C, et al
    A rapid HPV typing assay to support global cervical cancer screening and risk-based management: A cross-sectional study.
    Int J Cancer. 2023 Sep 29. doi: 10.1002/ijc.34698.
    PubMed     Abstract available
    
    
    
64. MUNGO C, Osongo CO, Ambaka J, Omoto J, et al
    Efficacy of thermal ablation for treatment of biopsy-confirmed high-grade cervical precancer among women living with HIV in Kenya.
    Int J Cancer. 2023 Sep 15. doi: 10.1002/ijc.34737.
    PubMed     Abstract available
    
    
    
65. WANG J, Edvardsson H, Strander B, Andrae B, et al
    Long-term follow-up of cervical cancer incidence after normal cytological findings.
    Int J Cancer. 2023 Sep 11. doi: 10.1002/ijc.34723.
    PubMed     Abstract available
    
    
    
66. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available
    
    
    
67. FERNANDEZ VILLALOBOS NV, Ruffieux Y, Haas AD, Chinogurei C, et al
    Cervical precancer and cancer incidence among insured women with and without HIV in South Africa.
    Int J Cancer. 2023 Sep 2. doi: 10.1002/ijc.34707.
    PubMed     Abstract available
    
    
    August 2023
68. WHITE C, Reynolds S, Murphy K, Keegan H, et al
    Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34685.
    PubMed     Abstract available
    
    
    July 2023
69. REBOLJ M, Sargent A, Njor SH, Cuschieri K, et al
    Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly.
    Int J Cancer. 2023;153:8-19.
    PubMed     Abstract available
    
    
    June 2023
70. QI L, Wang M, Jia Y, Wang Y, et al
    Impact of the COVID-19 pandemic on the hospital attendance of patients with primary cervical cancer in Heilongjiang, China.
    Int J Cancer. 2023 Jun 1. doi: 10.1002/ijc.34617.
    PubMed     Abstract available
    
    
    May 2023
71. PESOLA F, Rebolj M, Sasieni P
    Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.
    Int J Cancer. 2023;152:2061-2068.
    PubMed     Abstract available
    
    
    April 2023
72. TISLER A, Nygard M, Kivite-Urtane A, Berza N, et al
    Comment on "The European response to the WHO call to eliminate cervical cancer as a public health problem".
    Int J Cancer. 2023 Apr 19. doi: 10.1002/ijc.34540.
    PubMed    
    
    
    March 2023
73. CUZICK J, Adcock R, Kinney W, Castle PE, et al
    Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States.
    Int J Cancer. 2023 Mar 22. doi: 10.1002/ijc.34519.
    PubMed     Abstract available
    
    
    
74. WEVER BMM, van den Helder R, van Splunter AP, van Gent MDJM, et al
    DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples, and cervical scrapes.
    Int J Cancer. 2023 Mar 13. doi: 10.1002/ijc.34504.
    PubMed     Abstract available
    
    
    
75. DONG L, Nygard M, Stoer NC, Klungsoyr O, et al
    Real-World Effectiveness of Hpv Vaccination Against Cervical Neoplasia Among Birth Cohorts Ineligible for Routine Vaccination.
    Int J Cancer. 2023 Mar 3. doi: 10.1002/ijc.34489.
    PubMed     Abstract available
    
    
    February 2023
76. HERZOG C, Vavourakis CD, Barrett JE, Karbon G, et al
    HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia.
    Int J Cancer. 2023 Feb 21. doi: 10.1002/ijc.34477.
    PubMed     Abstract available
    
    
    December 2022
77. BARRETT JE, Jones A, Evans I, Herzog C, et al
    The WID-EC test for the detection and risk prediction of endometrial cancer.
    Int J Cancer. 2022 Dec 19. doi: 10.1002/ijc.34406.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.